Medivation Company Profile (NASDAQ:MDVN)

About Medivation

Medivation logoMedivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MDVN
  • CUSIP: 58501N10
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $77.41
  • 200 Day Moving Average: $61.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 36.36
  • P/E Growth: 0.00
  • Market Cap: $N/A
  • Beta: 0.6
  • Net Margins: -17.24%
  • Return on Equity: 17.57%
  • Return on Assets: 9.63%
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 4.32%
  • Quick Ratio: 4.32%
Additional Links:
Companies Related to Medivation:

Analyst Ratings

Consensus Ratings for Medivation (NASDAQ:MDVN) (?)
Ratings Breakdown: 1 Sell Rating, 15 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.06)
Consensus Price Target: $75.73 (7.01% downside)

Analysts' Ratings History for Medivation (NASDAQ:MDVN)
DateFirmActionRatingPrice TargetDetails
10/9/2016BMO Capital MarketsReiterated RatingHoldView Rating Details
9/28/2016Cowen and CompanyReiterated RatingHoldView Rating Details
9/28/2016Canaccord GenuityReiterated RatingBuyView Rating Details
9/14/2016SunTrust Banks, Inc.Reiterated RatingNeutralView Rating Details
8/22/2016Maxim GroupSet Price TargetBuy$76.00View Rating Details
8/23/2016Credit Suisse GroupDowngradeOutperform -> Neutral$81.50View Rating Details
8/23/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details
8/22/2016Citigroup Inc.DowngradeBuy -> Neutral$73.00 -> $81.50View Rating Details
8/22/2016WedbushDowngradeOutperform -> Neutral$81.50View Rating Details
8/22/2016Brean CapitalDowngradeBuy -> HoldView Rating Details
8/22/2016Barclays PLCDowngradeOverweight -> Equal Weight$70.00 -> $81.00View Rating Details
8/10/2016Leerink SwannSet Price TargetHold$64.00View Rating Details
8/10/2016Jefferies Group LLCReiterated RatingHold$56.00 -> $60.00View Rating Details
8/10/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
5/7/2016Royal Bank of CanadaReiterated RatingSector Perform$40.00 -> $70.00View Rating Details
5/4/2016MizuhoDowngradeNeutral -> Underperform$150.00View Rating Details
5/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$44.00View Rating Details
4/4/2016BTIG ResearchReiterated RatingHoldView Rating Details
2/19/2016Bank of America CorpInitiated CoverageBuy$45.00View Rating Details
1/31/2016William BlairReiterated RatingOutperform$83.00View Rating Details
9/15/2015NomuraInitiated CoverageBuy$140.00View Rating Details
3/25/2015J P Morgan Chase & CoBoost Price TargetOverweight$130.00 -> $148.00View Rating Details
(Data available from 2/25/2015 forward)


Earnings History for Medivation (NASDAQ:MDVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$0.27$0.29$214.52 million$206.00 millionViewN/AView Earnings Details
5/5/2016Q116$0.23$0.11$197.01 million$182.50 millionViewListenView Earnings Details
2/25/2016Q415$0.25$0.29$373.85 million$377.74 millionViewListenView Earnings Details
11/5/2015Q315$0.33$0.35$236.70 million$260.70 millionViewN/AView Earnings Details
8/6/2015Q215$0.45$0.58$155.22 million$175.67 millionViewN/AView Earnings Details
5/7/2015Q115$0.27$0.17$149.00 million$129.20 millionViewN/AView Earnings Details
2/25/2015Q414$1.33$1.96$233.19 million$274.70 millionViewN/AView Earnings Details
11/6/2014Q314$0.84$0.96$182.00 million$200.48 millionViewN/AView Earnings Details
8/7/2014Q214$0.24$0.60$126.46 million$148.09 millionViewN/AView Earnings Details
5/8/2014Q114($0.09)($0.18)$94.64 million$87.19 millionViewN/AView Earnings Details
2/27/2014Q413($0.08)$0.03$72.68 million$96.61 millionViewN/AView Earnings Details
1/30/2014Q4($0.14)($0.43)ViewN/AView Earnings Details
11/12/2013Q313($0.26)($0.18)$60.13 million$108.50 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.21)($0.07)$59.35 million$70.15 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.45)($0.36)$38.54 million$46.15 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.52)($0.43)$34.36 million$37.16 millionViewN/AView Earnings Details
11/9/2012Q312($0.03)($0.06)$52.11 million$64.80 millionViewN/AView Earnings Details
8/9/2012$0.23($0.15)ViewN/AView Earnings Details
5/8/2012$1.19$0.01ViewN/AView Earnings Details
2/29/2012($0.25)($0.31)ViewN/AView Earnings Details
11/9/2011($0.31)($0.29)ViewN/AView Earnings Details
8/9/2011($0.25)($0.27)ViewN/AView Earnings Details
5/6/2011($0.24)($0.24)ViewN/AView Earnings Details
3/16/2011($0.17)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Medivation (NASDAQ:MDVN)
Current Year EPS Consensus Estimate: $1.27 EPS
Next Year EPS Consensus Estimate: $2.24 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20165$0.18$0.26$0.21
Q3 20162$0.24$0.25$0.25
Q4 20162$0.31$0.32$0.32
(Data provided by Zacks Investment Research)


Dividend History for Medivation (NASDAQ:MDVN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Medivation (NASDAQ:MDVN)
Insider Ownership Percentage: 3.54%
Institutional Ownership Percentage: 87.55%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016Andrew Kenneth William PowellSVPSell2,578$60.42$155,762.76View SEC Filing  
5/6/2016Rick BierlyCFOSell10,340$59.76$617,918.40View SEC Filing  
3/14/2016Dawn SvoronosDirectorSell6,000$38.90$233,400.00View SEC Filing  
3/4/2016David HungCEOSell5,085$41.10$208,993.50View SEC Filing  
3/4/2016Mohammad HirmandInsiderSell1,525$41.10$62,677.50View SEC Filing  
3/4/2016Rick BierlyCFOSell2,998$40.00$119,920.00View SEC Filing  
2/4/2016David HungCEOSell6,350$31.18$197,993.00View SEC Filing  
1/19/2016Clarence Patrick MachadoDirectorSell75,000$37.34$2,800,500.00View SEC Filing  
1/4/2016Joseph M LobackiInsiderSell3,065$46.50$142,522.50View SEC Filing  
12/14/2015W Anthony VernonDirectorBuy15,000$40.69$610,350.00View SEC Filing  
12/3/2015David HungCEOSell10,950$43.10$471,945.00View SEC Filing  
12/3/2015Mohammad HirmandInsiderSell1,075$43.40$46,655.00View SEC Filing  
9/25/2015Clarence Patrick MachadoDirectorSell71,980$42.36$3,049,072.80View SEC Filing  
9/8/2015Dawn SvoronosDirectorSell3,100$89.15$276,365.00View SEC Filing  
6/4/2015Clarence Patrick MachadoDirectorSell36,000$117.43$4,227,480.00View SEC Filing  
5/20/2015Rick BierlyCFOSell1,000$130.00$130,000.00View SEC Filing  
5/5/2015Rick BierlyCFOSell1,615$125.00$201,875.00View SEC Filing  
5/4/2015Rick BierlyCFOSell2,170$124.70$270,599.00View SEC Filing  
4/15/2015Rick BierlyCFOSell3,000$132.20$396,600.00View SEC Filing  
3/16/2015Jennifer J RhodesInsiderSell1,390$130.92$181,978.80View SEC Filing  
3/2/2015David HungCEOSell100,891$120.83$12,190,659.53View SEC Filing  
3/2/2015Dawn SvoronosDirectorSell3,350$119.75$401,162.50View SEC Filing  
3/2/2015Jennifer J RhodesInsiderSell2,000$122.00$244,000.00View SEC Filing  
2/27/2015Kathryn E FalbergDirectorBuy25,000$117.67$2,941,750.00View SEC Filing  
2/26/2015David HungCEOSell19,109$120.12$2,295,373.08View SEC Filing  
2/26/2015Jennifer J RhodesInsiderSell3,089$119.29$368,486.81View SEC Filing  
2/4/2015David HungCEOSell3,190$100.48$320,531.20View SEC Filing  
1/27/2015Clarence Patrick MachadoDirectorSell36,000$105.32$3,791,520.00View SEC Filing  
1/20/2015David HungCEOSell100,000$108.14$10,814,000.00View SEC Filing  
12/3/2014Clarence Patrick MachadoDirectorSell1,580$113.00$178,540.00View SEC Filing  
12/3/2014David HungCEOSell5,420$113.00$612,460.00View SEC Filing  
9/18/2014Lynn SeelyInsiderSell55,000$98.47$5,415,850.00View SEC Filing  
9/9/2014Lynn SeelyInsiderSell20,000$94.60$1,892,000.00View SEC Filing  
8/27/2014Lynn SeelyInsiderSell20,000$89.42$1,788,400.00View SEC Filing  
8/13/2014Lynn SeelyInsiderSell20,000$83.62$1,672,400.00View SEC Filing  
8/12/2014Lynn SeelyInsiderSell25,500$83.02$2,117,010.00View SEC Filing  
7/22/2014Lynn SeelyInsiderSell7,500$73.96$554,700.00View SEC Filing  
7/2/2014Lynn SeelyInsiderSell12,000$79.02$948,240.00View SEC Filing  
6/18/2014Lynn SeelyInsiderSell15,000$74.75$1,121,250.00View SEC Filing  
2/18/2014Clarence Patrick MachadoCFOSell40,000$82.79$3,311,600.00View SEC Filing  
2/11/2014Clarence Patrick MachadoCFOSell40,000$80.83$3,233,200.00View SEC Filing  
2/5/2014Clarence Patrick MachadoCFOSell40,000$73.46$2,938,400.00View SEC Filing  
1/28/2014Clarence Patrick MachadoCFOSell40,000$75.43$3,017,200.00View SEC Filing  
1/27/2014David HungCEOSell150,000$73.50$11,025,000.00View SEC Filing  
1/21/2014Clarence Patrick MachadoCFOSell40,000$76.29$3,051,600.00View SEC Filing  
1/21/2014Jennifer RhodesInsiderSell14,000$76.28$1,067,920.00View SEC Filing  
12/3/2013Clarence Patrick MachadoCFOSell5,425$62.66$339,930.50View SEC Filing  
12/3/2013David HungCEOSell15,050$62.61$942,280.50View SEC Filing  
10/24/2013Cheryl CohenInsiderSell50,000$64.25$3,212,500.00View SEC Filing  
8/2/2013Cheryl CohenInsiderSell25,000$59.31$1,482,750.00View SEC Filing  
7/5/2013David HungCEOSell30,885$55.45$1,712,573.25View SEC Filing  
7/3/2013Cheryl CohenInsiderSell25,000$54.01$1,350,250.00View SEC Filing  
10/4/2012David HungCEOSell50,000$57.92$2,896,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Medivation (NASDAQ:MDVN)
News IconMedivation's (MDVN) “Buy” Rating Reiterate at the Credit Suisse Group - Petro Global News 24 (NASDAQ:MDVN) - February 24 at 9:33 AM
News IconAnalyst Consensus Estimates & Projections are in For Shares of Medivation, Inc. (NASDAQ:MDVN) - Aiken Advocate (NASDAQ:MDVN) - February 23 at 6:47 AM
News IconWhere is Medivation, Inc. (NASDAQ:MDVN) Headed Near Term? - Rockville Register (NASDAQ:MDVN) - February 22 at 8:19 AM
News IconAnalysts Peer Into Their Crystal Balls For Medivation, Inc. (NASDAQ:MDVN): Where Is It headed? - Winfield Review (NASDAQ:MDVN) - February 21 at 6:25 PM logoClovis, Tesaro Soar on Astrazeneca Phase Three News (NASDAQ:MDVN) - February 17 at 2:34 PM logoPfizer May Be Another IBM (NASDAQ:MDVN) - February 3 at 7:12 PM logoRecent Pfizer Press Releases (NASDAQ:MDVN) - January 31 at 7:22 PM logoPfizer quarterly revenue slips 3 percent (NASDAQ:MDVN) - January 31 at 7:22 PM logoPfizer's profit misses as Prevnar sales lag, costs rise (NASDAQ:MDVN) - January 31 at 7:22 PM
News IconMedivation, Inc. (NASDAQ:MDVN) Valuation According To Analysts - UK Market News (NASDAQ:MDVN) - January 26 at 5:59 AM
News IconEarnings in Full Force, Analysts Take Aim at Medivation, Inc. (NASDAQ:MDVN) - Wall Street Beacon (NASDAQ:MDVN) - January 26 at 5:59 AM
News IconRating Sentiment Worth Mentioning Today: This is what analysts have to say about Medivation Inc (NASDAQ:MDVN ... - Fair View Times (NASDAQ:MDVN) - January 19 at 5:03 AM
News IconEarnings Take Center Stage; Analysts Weighing in on Medivation, Inc. (NASDAQ:MDVN) - Aiken Advocate (NASDAQ:MDVN) - January 19 at 5:03 AM
News IconMedivation Inc MDVN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MDVN) - January 14 at 6:33 PM
News IconCanaccord Genuity Reiterates Buy at Medivation Inc. (NASDAQ: MDVN) - BNB Daily (blog) (NASDAQ:MDVN) - December 28 at 11:24 PM logoThe Best Biopharma CEOs of 2016 Are... (NASDAQ:MDVN) - December 19 at 10:32 AM logoXtandi From Pfizer Inc. (NYSE:PFE) Fails To Meet The Primary Endpoint: Phase 4 PLATO Study Reveals (NASDAQ:MDVN) - December 16 at 7:06 PM logoPenny Ante: Portage Biotech Inc. (PTGEF) Will Unveil Massive Potential (NASDAQ:MDVN) - November 22 at 10:13 AM
News IconPenny Ante: Portage Biotech Will Unveil Massive Potential, PTGEF (NASDAQ:MDVN) - November 21 at 11:24 AM logoBristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare Sector Paid Off? (NASDAQ:MDVN) - November 18 at 5:44 PM
News IconSell-side Taking Aim at Shares of Medivation, Inc. (NASDAQ:MDVN) - CSZ News (NASDAQ:MDVN) - November 17 at 9:53 AM
News IconMedivation, Inc. MDVN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:MDVN) - November 16 at 6:26 PM
News IconWhat are Analysts Expecting for Medivation, Inc. (NASDAQ:MDVN ... - CSZ News (NASDAQ:MDVN) - November 4 at 9:19 AM logo30.1% Return Seen to Date on SmarTrend Medivation Call (MDVN) (NASDAQ:MDVN) - October 25 at 6:07 PM logoAfter FDA Approval, Merck Posts Better-Than-Expected Earnings (NASDAQ:MDVN) - October 25 at 11:10 AM logo5 Healthcare Stocks to Buy Despite a Clinton Victory (NASDAQ:MDVN) - October 25 at 11:10 AM logoBillionaire Ken Fisher Loves These Dividend Stocks (NASDAQ:MDVN) - October 21 at 6:07 PM
News IconMedivation, Inc. (NASDAQ:MDVN) – Broker Update - NewsDen (NASDAQ:MDVN) - October 19 at 11:04 AM logoMedivation Has Returned 30.1% Since SmarTrend Recommendation (MDVN) (NASDAQ:MDVN) - October 17 at 6:00 PM logoAnalyst Sees Risk Of Major M&A Action; Downgrades Pfizer Inc. (PFE) Price Target To $36 (NASDAQ:MDVN) - October 14 at 5:55 PM
News IconNew Analyst Ratings On Medivation, Inc. (NASDAQ:MDVN) - NewsDen (NASDAQ:MDVN) - October 13 at 9:40 AM logoNew Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly Improves Time to PSA Progression in Advanced Prostate Cancer, Compared with Placebo (NASDAQ:MDVN) - October 9 at 10:26 AM
News IconPre-Movers Stocks In Analysts Rate: Medivation, Inc. (NASDAQ:MDVN), Envision Healthcare Holdings, Inc. (NYSE ... - Street Wise Report (press release) (blog) (NASDAQ:MDVN) - October 7 at 11:10 AM
News IconUnusual Stocks Mover Hurt By Street Views: Medivation, Inc. (NASDAQ:MDVN), Provectus Biopharmaceuticals, Inc ... - Street Wise Report (press release) (blog) (NASDAQ:MDVN) - October 6 at 11:35 AM
News IconStocks Sparking Bullish Stampede across Wall Street: Medivation (NASDAQ:MDVN), Celldex Therapeutics (NASDAQ ... - Street Wise Report (press release) (blog) (NASDAQ:MDVN) - October 3 at 5:44 PM logoMedivation Shares Up 30.1% Since SmarTrend's Buy Recommendation (MDVN) (NASDAQ:MDVN) - September 30 at 6:14 PM logoMedivation, Inc. (NASDAQ:MDVN) Is Expected To Post EPS Of $0.43 - (NASDAQ:MDVN) - September 30 at 11:19 AM logoA Look at the Pfizer-Medivation Deal (NASDAQ:MDVN) - September 29 at 6:03 PM logoCompany Update (NASDAQ:MDVN): Medivation Inc Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016 (NASDAQ:MDVN) - September 29 at 11:10 AM logoMedivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016 (NASDAQ:MDVN) - September 28 at 5:51 PM
News IconNoticeable Stock: Masco Corporation (NYSE:MAS), Medivation, Inc. (NASDAQ:MDVN) - Newburgh Press (NASDAQ:MDVN) - September 28 at 11:02 AM logoPfizer (PFE) Closes Medivation (MDVN) Acquisition - (NASDAQ:MDVN) - September 28 at 11:02 AM logoMEDIVATION, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition or Dis (NASDAQ:MDVN) - September 28 at 11:01 AM logoPfizer Completes Acquisition of Medivation (NASDAQ:MDVN) - September 28 at 11:01 AM
News IconBlog Coverage US Pharma Giant Pfizer to Whole as one Complete Unit (NASDAQ:MDVN) - September 27 at 10:41 AM
News IconHC Stocks Assessment! Medivation Inc (MDVN), Pfizer Inc. (NYSE:PFE) - share market updates (press release) (NASDAQ:MDVN) - September 26 at 6:04 PM logoBillionaire James Dinan’s York Capital Initiated Stakes in These Companies (NASDAQ:MDVN) - September 26 at 10:45 AM


What is Medivation's stock symbol?

Medivation trades on the NASDAQ under the ticker symbol "MDVN."

Where is Medivation's stock going? Where will Medivation's stock price be in 2017?

18 equities research analysts have issued 1-year target prices for Medivation's stock. Their forecasts range from $44.00 to $150.00. On average, they expect Medivation's share price to reach $75.73 in the next year.

When will Medivation announce their earnings?

Medivation is scheduled to release their next quarterly earnings announcement on Thursday, November, 3rd 2016.

What are analysts saying about Medivation stock?

Here are some recent quotes from research analysts about Medivation stock:

  • Cowen and Company analysts commented, "Due to the September 28, 2016 acquisition of Medivation by Pfizer Inc., we are." (9/28/2016)

  • Barclays PLC analysts commented, "[W]e still think there is underappreciated scarcity value in MDVN shares given Xtandi's best-in-class profile and line-of-sight to tapping into new segments of the prostate market," Meacham wrote in a note.Related Link: Medivation Execs Making A Strong Case For Independent Growth Vs. Sale, Credit Suisse Says"Combine that with important data read-outs for Xtandi and talazoparib in breast cancer over the next 12 months, and we think the portfolio can support higher valuations even before factoring in synergies with strategic suitors," the analyst added.Meacham noted that although the biotech company's 2020 guidance ($2.5 billion plus in revenue) will be appreciated, "the details on longer treatment duration, increased visibility on timing for PROSPER / EMBARK read-outs, and insight into the pipeline strategy are more tangible." (5/6/2016)

  • Mizuho analysts commented, "unlikely" following its recent $150 million debt offering."We view this event (offering) as a sign that near-term take-out is unlikely, which led RLYP to take on non-dilutive, but expensive financing," analyst Irina Koffler began.As a result, Koffler lowered her takeout probability to 10 percent from 50 percent, as commercial partner Sanofi SA (ADR) (NYSE: SNY) is currently bidding on Medivation Inc (NASDAQ: MDVN). It remains unclear whether other companies are interested in Relypsa.The analyst also cut the takeout value from $34/share to $31 (stripping out the debt).Related Link: Brean's Yang: Relypsa Monthly Prescription Data Met Expectations, A Takeout Still "Probable"The Veltassa FactorHowever, Koffler didn't rule out the possibility of a takeout as Veltassa sales approach the $50 million–$100 million mark, stating, "We think this ramp could take over a year, at a minimum."In October 2015, the FDA has approved Veltassa to treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.The analyst noted that Relypsa can stay away from the markets until early 2017, and doesn't "think that Veltassa will be significantly large by that time to avoid another financing round if the company still remains stand-alone."Meanwhile, Koffler underlined the importance of Veltassa, as the analyst learned from the company that "Veltassa demonstrated ability to lower phosphate levels and blood pressure" in dialysis patients and patients with resistant hypertension. This may allow the company to pursue new label claims moving forward."Veltassa could be more attractive than we previously thought, but this may not help the stock in the short term," (5/4/2016)

  • According to Zacks Investment Research, "Although Medivation’s fourth quarter results were disappointing with the company missing earnings as well as revenue expectations, we are positive on the company’s efforts to expand Xtandi’s label. Xtandi sales should pick up with increased usage among urologists. The potential addition of head-to-head data against Casodex would help change the prescribing pattern of urologists leading to a boost in sales. We are also positive on the company's efforts to build an immuno-oncology franchise. However, Medivation’s dependence on a sole product for growth is concerning. Competition in the prostate cancer market is also intense. Meanwhile, Medivation received an acquisition offer from Sanofi which it rejected." (5/3/2016)

  • Jefferies Group LLC analysts commented, "We surveyed 50 physicians on current/projected Xtandi use and the trend appears to show increasing usage in most mCRPC populations especially after noting the STRIVE/TERRAIN data. Another key observation is duration of therapy for Xtandi extends meaningfully,further reversing a shortening duration seen in previous surveys." (5/2/2016)

How do I buy Medivation stock?

Shares of Medivation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Medivation stock cost?

One share of Medivation stock can currently be purchased for approximately $81.44.

Medivation (NASDAQ:MDVN) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Medivation (NASDAQ:MDVN)

Earnings History Chart

Earnings by Quarter for Medivation (NASDAQ:MDVN)

Dividend History Chart

Dividend Payments by Quarter for Medivation (NASDAQ:MDVN)

Last Updated on 2/25/2017 by Staff